Molecular Profiling for HER2+ Advanced Solid Tumors
Eric Van Cutsem, MD, PhD
David SP Tan, MBBS, PhD, PRCP
James Chih-Hsin Yang, MD, PhD
Kathleen Moore, MD, MS, FASCO
Diagnosis and Management of Metastatic PDAC
Efrat Dotan, MD
Shubham Pant, MD, MBBS
Chemotherapy Strategies for Metastatic PDAC
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Aparna R. Parikh, MD
Emerging Treatment Approaches for EBC
William J. Gradishar, MD
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
Management of HR+, HER2- High-Risk EBC
The Evolving Treatment Landscape for MBC: Emerging Therapies
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Alan Venook, MD
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
Expert Viewpoint: Optimizing Breast Cancer Treatment
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
Sara Lonardi, MD
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy
Wenxin Xu, MD
Sandy Srinivas, MD
Best Practices in Shared Decision-Making: Discussing ADT Regimens in mHSPC With Your Patient
Rana McKay, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.